Skip to content
DataLookout
Menu

NCT04194216

Antibiotic Prophylaxis in Rhinoplasty

StatusEnrolling by Invitation
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 20, 2026 to Dec 20, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Study completion pushed from Apr 20, 2027 to Apr 20, 2028
    • Interventions: Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4… to Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4…
    • Publications: details revised at 3 of 3 entries
  2. Notable Primary completion date: Dec 20, 2024 to Dec 20, 2026
    • Study completion date: Apr 20, 2025 to Apr 20, 2027
    v8
  3. Notable Primary completion date: Dec 20, 2023 to Dec 20, 2024
    • Study completion date: Apr 20, 2024 to Apr 20, 2025
    v7
  4. Minor Collaborators: 6 to 8v6
  5. Minor Collaborators: 2 to 6v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Primary completion date: Dec 2023 to Dec 20, 2023
    v4
  2. Notable Enrollment target: 1386 to 864
    • Start date: Jan 20, 2020 to May 20, 2020
    v3
  3. Minor Interventions: Intra-operative single intravenous dose of cephalexin 2 g or clindamycin 900 mg + Postoperative oral dose for a duration of 3 days of… to Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4…
    • Study description revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Postoperative Infection Rate
Timeframe: Seven days

Arms and interventions

Treatment arm AActive comparator

Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Treatment arm BActive comparator

Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

Drugs: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

Sites

1 site in 1 country

  • Facial Plastic and Reconstructive Surgery ClinicStanford, California, United States